Diplomat Now Dispensing IMBRUVICA® as First-Line Therapy for Chronic Lymphocytic Leukemia
FLINT, Mich.– March 14, 2016 – The nation’s largest independent specialty pharmacy announces new expanded indication for limited-distribution drug IMBRUVICA® (ibrutinib).
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for the new indication of IMBRUVICA® (ibrutinib). IMBRUVICA® was recently approved by the U.S. Food and Drug Administration as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).
To learn more about Diplomat’s oncology program, click here.
CLL is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. CLL is one of the most common types of leukemia in adults, accounting for about one-quarter of the new cases of leukemia. According to the American Cancer Society, it is estimated 18,960 people will be diagnosed with CLL in the United States in 2016. The average age at the time of diagnosis is around 71 years.
“The approval of IMBRUVICA® as a first-line treatment for patients with CLL represents an advancement in drug development and an important option for patients with this disease,” said Gary Kadlec, Diplomat president.
In February 2014, IMBRUVICA® was approved for the treatment of patients with CLL who had received at least one prior therapy. IMBRUVICA® is now approved to treat CLL patients regardless of their treatment history (both treatment-naïve and previously treated patients). In addition, IMBRUVICA® is approved to treat high-risk CLL patients who carry the del 17p, a genetic aberration that occurs when part of chromosome 17, the location of the tumor suppressor gene p53, has been lost or deleted.
Since its launch in 2013, IMBRUVICA® has been approved to treat patients with:
- Chronic lymphocytic leukemia (CLL)
- Chronic lymphocytic leukemia (CLL) with 17p deletion
- Waldenström’s macroglobulinemia (WM)
- Mantle cell lymphoma (MCL) who have received at least one prior therapy
IMBRUVICA® is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. Click here for complete IMBRUVICA® prescribing information.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education and Human Resources
810.768.9863 | firstname.lastname@example.org
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO173 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…6 days ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm2 weeks ago